Regeneron Pharmaceuticals, Inc. (REGN) — Stock Price, Chart & Analysis
Regeneron Pharmaceuticals, Inc. (REGN) is a Healthcare stock currently trading at $803.9, up 0.72% on the day. It carries a market capitalization of $82.77B and a trailing P/E ratio of 19.76. Over the past 52 weeks, REGN has traded between $541.00 and $859.34. Regeneron Pharmaceuticals, Inc. pays a dividend yielding 0.5%. View the live REGN chart, technical opinion, analyst ratings, fundamentals and latest news below.
Regeneron Pharmaceuticals, Inc. (REGN) key data
| Price | $803.9 |
| Change (today) | +0.72% |
| Previous close | $798.17 |
| Market cap | $82.77B |
| P/E ratio (TTM) | 19.76 |
| EPS (TTM) | $40.68 |
| Dividend yield | 0.5% |
| 52-week high | $859.34 |
| 52-week low | $541.00 |
| Beta | 0.19 |
| Avg. volume | 763.4K |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Regeneron Pharmaceuticals, Inc. (REGN)
How much does one share of Regeneron Pharmaceuticals, Inc. cost?
As of the latest update, one share of Regeneron Pharmaceuticals, Inc. (REGN) trades at $803.9 (+0.72% today).
What is Regeneron Pharmaceuticals, Inc.'s market cap?
Regeneron Pharmaceuticals, Inc. has a market capitalization of approximately $82.77B.
What is Regeneron Pharmaceuticals, Inc.'s P/E ratio?
Regeneron Pharmaceuticals, Inc. has a trailing price-to-earnings (P/E) ratio of 19.76.
What is Regeneron Pharmaceuticals, Inc.'s earnings per share (EPS)?
Regeneron Pharmaceuticals, Inc.'s trailing twelve-month EPS is $40.68.
Does Regeneron Pharmaceuticals, Inc. pay a dividend?
Yes — Regeneron Pharmaceuticals, Inc. pays a dividend with a yield of 0.5% ($3.76 per share annually).
What is Regeneron Pharmaceuticals, Inc.'s 52-week trading range?
Over the past year, REGN has traded between $541.00 and $859.34.
What is the analyst price target for Regeneron Pharmaceuticals, Inc.?
The mean analyst price target for Regeneron Pharmaceuticals, Inc. is $849.32. This is informational only and not investment advice.
Latest Regeneron Pharmaceuticals, Inc. (REGN) news
- Is Regeneron Stock a Bargain Below $800?News · Sep 22, 2026
- Will Fianlimab-Libtayo Trial Misstatement Lawsuits Change Regeneron Pharmaceuticals' (REGN) Pipeline-Driven Narrative?News · Sep 15, 2026
- Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?News · Sep 15, 2026
- Regeneron Pharmaceuticals (REGN) Could Be 5% Undervalued Following Trial Lawsuit NewsNews · Sep 15, 2026
- Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD MomentumNews · Sep 15, 2026
- Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive GrowthNews · Sep 12, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live REGN dashboard…